Drug details
Abecma (idecabtagene vicleucel suspension)
type of CAR-T Cell Therapies
Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy used to treat adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
The drug is often used to treat Multiple myeloma .
This drug may have the following side effects:
- nausea,
- diarrhea,
- fever,
- upper respiratory tract infection,
- musculoskeletal pain,
- headache,
- fatigue,
- cough,
- anemia
- cytokine release syndrome (CRS),
- decreased appetite,
- fluid retention (edema),
- infections,
- hypogammaglobulinemia,
- viral infections,
- encephalopathy,
- low white blood cells (neutropenia, leukopenia, lymphopenia),
- low platelets (thrombocytopenia), and
The following drugs are related to Abecma, either as a replacement or used together:
- Aphexda (motixafortide for injection)
- Aredia (pamidronate disodium)
- Blenrep (belantamab mafodotin-blmf for injection)
- BiCNU (carmustine)
- Velcade (bortezomib)
- Kyprolis (carfilzomib)
- Carvykti (ciltacabtagene autoleucel for iv injection)
- Darzalex Faspro (daratumumab and hyaluronidase-fihj injection)
- Darzalex (daratumumab intravenous injection)
- Empliciti (elotuzumab for injection)
- Evomela (melphalan for injection, for intravenous use)
- Farydak (panobinostat capsules)
- Sarclisa (isatuximab-irfc injection)
- Ninlaro (ixazomib capsules)
- Jaypirca (pirtobrutinib tablets)
- Revlimid (lenalidomide)
- Mozobil (plerixafor injection)
- Pomalyst (pomalidomide capsules)
- Xpovio (selinexor tablets)
- Tecvayli (teclistamab-cqyv injection)
- Zometa (zoledronic acid for inj)